Danaher is back in focus as analysts cluster around higher price targets, with several recent updates now sitting in the US$260 to US$275 range. These moves line up with research that highlights the company’s 2027 core growth framing, Q3 2026 trends, and how execution could feed through to margins, organic growth, and Danaher’s P/E multiple over time. Read on to see what is driving the shift in the analyst narrative and how you can track the story from here. Analyst Price Targets don't always...
Danaher has delivered an 18.1% gain over the past three years, and the question now is whether that share price level matches what its cash flows can reasonably support. Recent product clearances in its diagnostics and life sciences units add fresh information for investors who are trying to anchor Danaher’s valuation to the cash coming off the business rather than the headlines. The stock’s 18.1% return over three years places greater focus on whether the underlying cash generation is...
Danaher reported third quarter 2026 sales of US$6,554 million and net income of US$1,235 million, alongside FDA clearance for Beckman Coulter Diagnostics' Access MeMed BV rapid assay that distinguishes bacterial from viral infections in about 15 minutes and fits into existing lab workflows. The Access MeMed BV test gives Danaher another clinically meaningful diagnostic tool that can support antimicrobial stewardship efforts and potentially deepen consumables usage on its installed analyzer...
Danaher (DHR) is back in focus after U.S. regulators cleared the Access MeMed BV assay, a rapid test that helps clinicians distinguish bacterial from viral infections and potentially curb unnecessary antibiotic use. That regulatory win comes during a busy period for Danaher. Third quarter results on 21 October 2026 showed higher sales and earnings compared with a year earlier, and management lined up conference appearances at UBS and Jefferies to keep the story in front of healthcare...
Danaher (DHR) unit Cepheid wins FDA approval for Xpert Hemorrhagic Fever Panel to detect Ebola and several other hemorrhagic fever viruses. REad more here.
The conglomerate posted its latest set of quarterly earnings that morning.
Danaher delivered mixed Q3 results, with revenue up 8.3% y/y but growth driven mainly by acquisitions and tariff refunds. Read more on DHR stock here.
Thermo Fisher and Danaher stocks reversed higher Wednesday after reporting third-quarter metrics and full-year guidance.
Danaher's third-quarter earnings beat estimates by 9.9%, driven by stronger Biotechnology profitability, while it raised its 2026 adjusted earnings outlook.
This is the newest page. Registered accounts read further back.